Why did MOLN.SW stock jump pre-market today?

MOLN.SW stock rose pre-market on **CHF 3.55** as traders reacted to clinical and partner-related headlines. Higher volume of **128,132** shares signalled renewed buying interest ahead of potential trial readouts and an upcoming earnings date on 2026-03-12.

What is Meyka AI’s view on MOLN.SW stock valuation?

Meyka AI rates MOLN.SW with a score of **61.04** out of 100 (Grade B, HOLD). Key metrics include cash per share **CHF 2.79**, PB near **1.37**, and negative EPS **-1.62**, which point to valuation sensitive to pipeline success.

What price targets and forecast exist for MOLN.SW stock?

Meyka AI's forecast model projects a yearly price of **CHF 2.78**, implying a **21.55%** downside from **CHF 3.55**. We outline a near-term target range **CHF 2.50–CHF 4.00**, dependent on clinical and partnership outcomes.

What are the main risks for holders of MOLN.SW stock?

The main risks for MOLN.SW stock are binary clinical outcomes, continued negative earnings, and pipeline delays. Liquidity risk is limited by a strong current ratio, but clinical failure would likely push the price materially lower.

CH Stocks

MOLN.SW up 8.23% pre-market to CHF 3.55 on SIX: watch upcoming trial catalysts

ByDanny Kontos February 3, 2026February 3, 2026

We opened pre-market trading noting that MOLN.SW stock rose 8.23% to CHF 3.55 on the SIX exchange, driven by heavy intraday volume of 128,132 shares. The move makes Molecular Partners AG (MOLN.SW) one of today’s top gainers on the Switzerland market as investors react to clinical updates and partner-related headlines. We review why the price moved, connect recent news to key metrics, and outline what catalysts could sustain momentum in the near term using Meyka AI-powered market analysis.